HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: 288/4/E813    most recent 00266.2004v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (7) Citing Articles via Google Scholar Google Scholar Articles by Kim, S. Articles by Vaziri, N. D. Search for Related Content PubMed PubMed Citation Articles by Kim, S. Articles by Vaziri, N. D.

TRANSLATIONAL PHYSIOLOGY

Upregulation of hepatic LDL receptor-related protein in nephrotic syndrome: response to statin therapy

¹Division of Nephrology and Hypertension and ²Department of Physiology and Biophysics, University of California, Irvine, California

Submitted 22 June 2004 ; accepted in final form 28 November 2004

Nephrotic syndrome (N-S) is associated with elevated plasma concentration and impaired clearance of VLDL, chylomicrons (CM), and their atherogenic remnants. These abnormalities are largely due to lipoprotein lipase, hepatic triglyceride lipase, and VLDL receptor deficiencies and impaired HDL-mediated shuttling of apoE and apoC between the nascent and remnant VLDL and CM. LRP is a multifaceted endocytic receptor that is heavily expressed in the liver. LRP recognizes at least 30 different ligands including VLDL and CM remnants. These observations prompted the present study to discern the effect of N-S on hepatic LRP gene and protein expressions. The study further sought to explore the effect of lipid-lowering therapy on LRP expression in N-S. Sprague-Dawley rats were randomized to the N-S (given ip injections of puromycin aminonucleoside; 130 mg/kg on day 1, 60 mg/kg on day 14) and placebo-injected control groups. On day 14, animals were subdivided into statin-treated (rosuvastatin; 20 mg·kg^–1·day^–1 mixed with powdered chow) and untreated groups and studied on day 28. The untreated N-S group exhibited severe proteinuria, hypoalbuminemia, hypercholesterolemia, hypertriglyceridemia, and marked elevation of hepatic tissue LRP mRNA and protein abundance. Statin administration for 2 wk resulted in significant improvements of plasma lipid profile, proteinuria, and hypoalbuminemia as well as hepatic LRP mRNA and protein abundance. In contrast, statin administration had no significant effect on either plasma lipids or hepatic LRP levels in the normal control rats. In conclusion, N-S results in marked upregulation of hepatic LRP expression that is partly reversed with statin administration. These findings exclude depressed hepatic LRP expression as the primary cause of elevated plasma lipoprotein remnants in N-S.

proteinuria; hyperlipidemia; atherosclerosis; very-low-density lipoprotein; chylomicrons; ₂-macroglobulin; coagulation disorders; thrombosis; low-density lipoprotein

This article has been cited by other articles:

				A. Schmechel, M. Grimm, A. El-Armouche, G. Hoppner, A. P. Schwoerer, H. Ehmke, and T. Eschenhagen Treatment with atorvastatin partially protects the rat heart from harmful catecholamine effects Cardiovasc Res, April 1, 2009; 82(1): 100 - 106. [Abstract] [Full Text] [PDF]

				T. Fujita, S. Yasuda, Y. Kamata, K. Fujita, Y. Ohtani, Y. Kumagai, and M. Majima Contribution of Down-Regulation of Intestinal and Hepatic Cytochrome P450 3A to Increased Absorption of Cyclosporine A in a Rat Nephrosis Model J. Pharmacol. Exp. Ther., November 1, 2008; 327(2): 592 - 599. [Abstract] [Full Text] [PDF]

				S. Azhar, S. Medicherla, W.-J. Shen, Y. Fujioka, L. G. Fong, E. Reaven, and A. D. Cooper LDL and cAMP cooperate to regulate the functional expression of the LRP in rat ovarian granulosa cells J. Lipid Res., November 1, 2006; 47(11): 2538 - 2550. [Abstract] [Full Text] [PDF]